Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
|
|
CELL GENESYS INC (CEGE)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/05/2009 |
8-K
| Form 8-K - Current report |
| 04/30/2009 |
8-K
| Quarterly results |
| 03/09/2009 |
8-K
| Quarterly results |
| 11/06/2008 |
8-K
| Quarterly results |
| 08/01/2008 |
8-K
| Quarterly results |
| 05/01/2008 |
8-K
| Quarterly results |
| 02/28/2008 |
8-K
| Quarterly results |
| 11/01/2007 |
8-K
| Quarterly results |
| 08/07/2007 |
8-K
| Quarterly results |
| 05/10/2007 |
8-K
| Quarterly results |
| 03/01/2007 |
8-K
| Quarterly results |
| 11/02/2006 |
8-K
| Quarterly results |
| 08/03/2006 |
8-K
| Quarterly results |
| 05/09/2006 |
8-K
| Quarterly results |
| 02/22/2006 |
8-K
| Quarterly results |
| 11/04/2005 |
8-K
| Quarterly results|
Docs:
|
"CELL GENESYS REPORTS THIRD QUARTER 2005 FINANCIAL RESULTS SOUTH SAN FRANCISCO, CA, November 2, 2005 — Cell Genesys, Inc. reported a net loss of $27.3 million, or $0.60 per share for the quarter ended September 30, 2005. This compares with a net loss of $24.0 million, or $0.54 per share, for the same quarter in 2004. The increase in net loss in the current quarter compared to the third quarter of 2004 can be attributed to increased operating losses, resulting in part from greater expenditures on our GVAX ® vaccine for prostate cancer program. Cell Genesys ended the quarter with approximately $102.4 million in cash, cash equivalents and short-term investments. In addition, Cell Genesys held approximately 6.0 million shares of its former subsidiary, Abgenix, Inc., which had a market value of ..." |
|
| 07/26/2005 |
8-K
| Quarterly results|
Docs:
|
"CELL GENESYS REPORTS SECOND QUARTER 2005 FINANCIAL RESULTS SOUTH SAN FRANCISCO, CA, July 25, 2005 — Cell Genesys, Inc. reported a net loss of $27.4 million, or $0.60 per share, for the quarter ended June 30, 2005. This compares with a net loss of $26.0 million, or $0.58 per share, for the quarter ended June 30, 2004. The slight increase in net loss quarter to quarter is due primarily to the absence of gains from the sale of marketable securities. Cell Genesys ended the quarter with approximately $120.6 million in cash, cash equivalents and short-term investments, and in addition, held approximately 6.6 million shares of its former subsidiary, Abgenix, Inc., which as of June 30, 2005 had a market value of approximately $56.8 million. The company's research and development costs for the quar..." |
|
| 04/28/2005 |
8-K
| Quarterly results|
Docs:
|
"CELL GENESYS REPORTS FIRST QUARTER 2005 FINANCIAL RESULTS SOUTH SAN FRANCISCO, CA, April 27, 2005 — Cell Genesys, Inc. reported a net loss of $29.3 million, or $0.65 per share, for the quarter ended March 31, 2005. This compares with a net loss of $20.9 million, or $0.52 per share, in the same quarter of 2004. The increase in net loss quarter-to-quarter is due primarily to the absence of gains from the sales of marketable securities and the timing of revenue payments from certain licensing agreements. Cell Genesys ended the quarter with approximately $144.5 million in cash, cash equivalents and short-term investments, including restricted cash and investments. In addition, at the end of the first quarter, Cell Genesys held approximately 6.6 million shares of its former subsidiary, Abgenix,..." |
|
|
|